Staff Reports
Americans are tired of surprise drug bills and a healthcare system that feels rigged against patients. The latest congressional spotlight focused on one obvious suspect: pharmacy benefit managers, or PBMs. A recent House Education & the Workforce Subcommittee hearing put PBMs on the hot seat and pushed concrete reform language lawmakers can vote on — and that is the real story here.
What the hearing exposed
At the “Profits Over Patients” hearing, witnesses and lawmakers peeled back the curtain on how PBMs operate. Subcommittee Chairman Rick W. Allen led the session. Experts like Dr. Mariana Socal from Johns Hopkins and Hannah Anderson of the America First Policy Institute testified that a few giant PBMs control much of the market and that hidden deals can steer patients and employers into higher costs. The testimony and hearing packet spelled out the problem: opaque kickbacks and referral fees between PBMs, brokers, and consultants can distort competition and raise prescription drug prices for people with employer plans.
PBM kickbacks and H.R. 7895: a simple fix?
The committee didn’t just complain — it advanced a bill. H.R. 7895, the PBM Kickback Prohibition Act, would ban kickbacks and referral fees from PBMs to brokers and benefits consultants. The bill was marked up in committee and placed on the Union Calendar for floor consideration. In plain language: lawmakers want to stop middlemen from funneling money to each other in ways that hide true drug costs. If you’re surprised by the scandal, congratulations — you’ve been paying attention. If you’re not surprised, you’ve probably been paying the bill.
Why this matters for costs, competition, and rural care
This debate isn’t academic. National health spending is ballooning, and many rural hospitals are already on shaky ground. Witnesses cited projections showing per-person healthcare spending rising rapidly in coming years. They also pointed to more than a hundred rural hospital closures since 2010 and the ongoing vulnerability of many small hospitals. When PBMs and secret deals drive prices up, employers, patients, and local hospitals all feel it. Transparency and competition are practical tools to lower prescription drug costs and help keep rural clinics open — not another Washington takeover.
Congress has a choice. Republicans on the committee are pushing market-based fixes: transparency, banning PBM kickbacks, and boosting competition so generics get to market faster. Democrats often answer with bigger federal programs that centralize control. If you care about lower drug prices, less bureaucracy, and protecting rural hospitals, then stripping away hidden fees and making prices public is a good place to start. Call it small-government reform with a big impact — and don’t be fooled by those who insist the only answer is more government control of healthcare.
